The Nimbus Advanced Active wound dressing is a superabsorbent dressing that provides the controlled release of a protease inhibitor, antioxidants, and epidermal growth factor to stimulate skin regeneration. Based on nontoxic, long chain polymers with high charge density and high molecular weight, the dressing evokes a physical action on microbes, destroying them at the cellular level. Since the active agent is permanently bonded to the dressing surface, there is no leaching and no depletion of the antimicrobial reservoir. Also, antibiotic resistance cannot be developed, as the large size of Nimbus polymers make their internalization by the bacteria impossible. The technology is highly effective against a multitude of germs, including Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus (VRE), two of the most significant antibiotic-resistant organisms responsible for hospital infections.

The dressing has broad applicability to all classes of wounds, including difficult to treat thermal and chemical burns, and provides a moist wound healing environment. The Nimbus Advanced Active wound dressing is a product of Quick-Med Technologies (Gainesville, FL, USA), and has been selected by the U.S. Army for evaluation in the healing of vesicant injuries, following significant improvements in wound healing in vitro experiments with chemically injured human tissue. The next phase of the research involves animal studies that will be conducted at Battelle Memorial Institute (Columbus, OH, USA).

"Preliminary findings of the in vivo animal studies demonstrate that Nimbus Advanced Active can combine actives and control their release to enhance wound healing. These agents can perform additional functions without diminishing the dressing's antimicrobial performance,” said Jerry Olderman, vice president of research and development at QuickMed. "Nimbus Advanced Active is the ultimate multifunctional dressing, with applicability for acute and chronic wounds. Its multiple agents will aid wound healing of many types of acute and chronic injuries. We look forward to receiving the final report on the animal study confirming the results of its healing capabilities.”

Related Links:
Quick-Med Technologies
Battelle Memorial Institute